Which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?
Riyaz Shah • 8 Jul 2022
NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?
Riyaz Shah • 29 Jan 2020
Building a clinical research platform to capture and leverage data from cancer care in Germany